Antitumor pharmacological research in the era of personalized medicine

被引：2

作者：

Huang, Min ^{[1
,2
]}

Geng, Mei-yu ^{[1
,2
]}

Ding, Jian ^{[1
,2
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China

来源：

ACTA PHARMACOLOGICA SINICA | 2022年 / 43卷 / 12期

基金：

中国国家自然科学基金;

关键词：

personalized medicine; anticancer drug discovery; oncogene addiction; non-oncogene addiction; combination therapy; THERAPEUTIC RESPONSE; ANTICANCER THERAPY; CANCER-THERAPY; INHIBITORS; FGFR; BIOMARKERS; ADDICTION; ONCOGENE;

D O I：

10.1038/s41401-022-01023-0

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Anticancer drug discovery has yielded unprecedented progress in recent decades, resulting in the approval of innovative treatment options for patients and the successful implementation of personalized medicine in clinical practice. This remarkable progress has also reshaped the research scope of pharmacological research. This article, as a tribute to cancer research at Shanghai Institute of Materia Medica in celebration of the institute's 90th birthday, provides an overview of the conceptual revolution occurring in anticancer therapy, and summarizes our recent progress in the development of molecularly targeted therapeutics and exploration of new strategies in personalized medicine. With this review, we hope to provide a glimpse into how antitumor pharmacological researchers have embraced the new era of personalized medicine research and to propose a future path for anticancer drug discovery and pharmacological research.

引用

页码：3015 / 3020

页数：6

共 46 条

[1] Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models [J].

Ai, Jing ;

Chen, Yi ;

Peng, Xia ;

Ji, Yinchun ;

Xi, Yong ;

Shen, Yanyan ;

Yang, Xinying ;

Su, Yi ;

Sun, Yiming ;

Gao, Yinglei ;

Ma, Yuchi ;

Xiong, Bing ;

Shen, Jingkang ;

Ding, Jian ;

Geng, Meiyu .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (04) :751-762

[2] Integrating predictive biomarkers and classifiers into oncology clinical development programmes [J].

Beckman, Robert A. ;

Clark, Jason ;

Chen, Cong .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (10) :735-748

[3] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity [J].

Canon, Jude ;

Rex, Karen ;

Saiki, Anne Y. ;

Mohr, Christopher ;

Cooke, Keegan ;

Bagal, Dhanashri ;

Gaida, Kevin ;

Holt, Tyler ;

Knutson, Charles G. ;

Koppada, Neelima ;

Lanman, Brian A. ;

Werner, Jonathan ;

Rapaport, Aaron S. ;

San Miguel, Tisha ;

Ortiz, Roberto ;

Osgood, Tao ;

Sun, Ji-Rong ;

Zhu, Xiaochun ;

McCarter, John D. ;

Volak, Laurie P. ;

Houk, Brett E. ;

Fakih, Marwan G. ;

O'Neil, Bert H. ;

Price, Timothy J. ;

Falchook, Gerald S. ;

Desai, Jayesh ;

Kuo, James ;

Govindan, Ramaswamy ;

Hong, David S. ;

Ouyang, Wenjun ;

Henary, Haby ;

Arvedson, Tara ;

Cee, Victor J. ;

Lipford, J. Russell .

NATURE, 2019, 575 (7781) :217-+

[4]

Chen XX, 2022, CANCER RES, V82

[5] Kinase drug discovery 20 years after imatinib: progress and future directions [J].

Cohen, Philip ;

Cross, Darren ;

Janne, Pasi A. .

NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (07) :551-569

[6] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate [J].

Dang, Lenny ;

White, David W. ;

Gross, Stefan ;

Bennett, Bryson D. ;

Bittinger, Mark A. ;

Driggers, Edward M. ;

Fantin, Valeria R. ;

Jang, Hyun Gyung ;

Jin, Shengfang ;

Keenan, Marie C. ;

Marks, Kevin M. ;

Prins, Robert M. ;

Ward, Patrick S. ;

Yen, Katharine E. ;

Liau, Linda M. ;

Rabinowitz, Joshua D. ;

Cantley, Lewis C. ;

Thompson, Craig B. ;

Heiden, Matthew G. Vander ;

Su, Shinsan M. .

NATURE, 2009, 462 (7274) :739-U52

[7] Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all? [J].

de Jonge, M. J. A. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) :1351-1356

[8] Clinical Challenges of Immune Checkpoint Inhibitors [J].

de Miguel, Maria ;

Calvo, Emiliano .

CANCER CELL, 2020, 38 (03) :326-333

[9]

Dienstmann R, 2012, ANN ONCOL, V23, P116

[10] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

← 1 2 3 4 5 →